scholarly journals An interactive database for the investigation of high-density peptide microarray guided interaction patterns and antivenom cross-reactivity

2020 ◽  
Vol 14 (6) ◽  
pp. e0008366
Author(s):  
Kamille E. Krause ◽  
Timothy P. Jenkins ◽  
Carina Skaarup ◽  
Mikael Engmark ◽  
Nicholas R. Casewell ◽  
...  
Toxins ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 393 ◽  
Author(s):  
Line Ledsgaard ◽  
Timothy Jenkins ◽  
Kristian Davidsen ◽  
Kamille Krause ◽  
Andrea Martos-Esteban ◽  
...  

Antivenom cross-reactivity has been investigated for decades to determine which antivenoms can be used to treat snakebite envenomings from different snake species. Traditionally, the methods used for analyzing cross-reactivity have been immunodiffusion, immunoblotting, enzyme-linked immunosorbent assay (ELISA), enzymatic assays, and in vivo neutralization studies. In recent years, new methods for determination of cross-reactivity have emerged, including surface plasmon resonance, antivenomics, and high-density peptide microarray technology. Antivenomics involves a top-down assessment of the toxin-binding capacities of antivenoms, whereas high-density peptide microarray technology may be harnessed to provide in-depth knowledge on which toxin epitopes are recognized by antivenoms. This review provides an overview of both the classical and new methods used to investigate antivenom cross-reactivity, the advantages and disadvantages of each method, and examples of studies using the methods. A special focus is given to antivenomics and high-density peptide microarray technology as these high-throughput methods have recently been introduced in this field and may enable more detailed assessments of antivenom cross-reactivity.


2020 ◽  
Vol 205 (1) ◽  
pp. 290-299
Author(s):  
Thomas Osterbye ◽  
Morten Nielsen ◽  
Nadine L. Dudek ◽  
Sri H. Ramarathinam ◽  
Anthony W. Purcell ◽  
...  

2010 ◽  
Vol 13 (9) ◽  
pp. 777-789 ◽  
Author(s):  
Xiaoming Han ◽  
Tatsuhiko Sonoda ◽  
Takeshi Mori ◽  
Go Yamanouchi ◽  
Takayuki Yamaji ◽  
...  

2014 ◽  
Vol 86 (12) ◽  
pp. 5844-5850 ◽  
Author(s):  
Huan Qi ◽  
Fei Wang ◽  
Valery A. Petrenko ◽  
Aihua Liu

2017 ◽  
Vol 11 (7) ◽  
pp. e0005768 ◽  
Author(s):  
Mikael Engmark ◽  
Bruno Lomonte ◽  
José María Gutiérrez ◽  
Andreas H. Laustsen ◽  
Federico De Masi ◽  
...  

2020 ◽  
Author(s):  
Yang Li ◽  
Danyun Lai ◽  
Qing Lei ◽  
Zhaowei Xu ◽  
Hongyan Hou ◽  
...  

Serological test plays an essential role in monitoring and combating COVID-19 pandemic. Recombinant spike protein (S protein), especially S1 protein is one of the major reagents for serological tests. However, the high cost in production of S protein, and the possible cross-reactivity with other human coronaviruses poses unneglectable challenges. Taking advantage of a peptide microarray of full spike protein coverage, we analyzed 2,434 sera from 858 COVID-19 patients, sera from 63 asymptomatic patients and 610 controls collected from multiple clinical centers. Based on the results of the peptide microarray, we identified several S protein derived 12-mer peptides that have high diagnosis performance. Particularly, for monitoring IgG response, one peptide (aa 1148-1159 or S2-78) has a comparable sensitivity (95.5%, 95% CI 93.7-96.9%) and specificity (96.7%, 95% CI 94.8-98.0%) to that of S1 protein for detection of both COVID-19 patients and asymptomatic infections. Furthermore, the performance of S2-78 IgG for diagnosis was successfully validated by ELISA with an independent sample cohort. By combining S2-78/ S1 with other peptides, a two-step strategy was proposed to ensure both the sensitivity and specificity of S protein based serological assay. The peptide/s identified in this study could be applied independently or in combination with S1 protein for accurate, affordable, and accessible COVID-19 diagnosis.


2016 ◽  
Vol 15 (4) ◽  
pp. 1360-1380 ◽  
Author(s):  
Michael Hecker ◽  
Brit Fitzner ◽  
Matthias Wendt ◽  
Peter Lorenz ◽  
Kristin Flechtner ◽  
...  

mBio ◽  
2018 ◽  
Vol 9 (2) ◽  
Author(s):  
Nischay Mishra ◽  
Adrian Caciula ◽  
Adam Price ◽  
Riddhi Thakkar ◽  
James Ng ◽  
...  

ABSTRACTZika virus (ZIKV) is implicated in fetal stillbirth, microcephaly, intracranial calcifications, and ocular anomalies following vertical transmission from infected mothers. In adults, infection may trigger autoimmune inflammatory polyneuropathy. Transmission most commonly follows the bite of infectedAedesmosquitoes but may also occur through sexual intercourse or receipt of blood products. Definitive diagnosis through detection of viral RNA is possible in serum or plasma within 10 days of disease onset, in whole blood within 3 weeks of onset, and in semen for up to 3 months. Serological diagnosis is nonetheless critical because few patients have access to molecular diagnostics during the acute phase of infection and infection may be associated with only mild or inapparent disease that does not prompt molecular testing. Serological diagnosis is confounded by cross-reactivity of immune sera with other flaviviruses endemic in the areas where ZIKV has recently emerged. Accordingly, we built a high-density microarray comprising nonredundant 12-mer peptides that tile, with one-residue overlap, the proteomes of Zika, dengue, yellow fever, West Nile, Ilheus, Oropouche, and chikungunya viruses. Serological analysis enabled discovery of a ZIKV NS2B 20-residue peptide that had high sensitivity (96.0%) and specificity (95.9%) versus natural infection with or vaccination against dengue, chikungunya, yellow fever, West Nile, tick-borne encephalitis, or Japanese encephalitis virus in a microarray assay and an enzyme-linked immunosorbent assay (ELISA) of early-convalescent-phase sera (2 to 3 weeks after onset of symptomatic infection).IMPORTANCEThe emergence of Zika virus (ZIKV) as a teratogen is a profound challenge to global public health. Molecular diagnosis of infection is straightforward during the 3-week period when patients are viremic. However, serological diagnosis thereafter of historical exposure has been confounded by cross-reactivity. Using high-density peptide arrays that tile the proteomes of a selection of flaviviruses to identify a ZIKV-specific peptide, we established two assays that enable sensitive and specific diagnosis of exposure to ZIKV. These assays may be useful in guiding clinical management of mothers at risk for potential exposure to ZIKV and enable insights into the epidemiology of ZIKV infections.


Sign in / Sign up

Export Citation Format

Share Document